Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Abstral receives marketing approval in Germany for breakthrough cancer pain

Dec. 12, 2008

Perampanel well tolerated in phase II study in patients with refractory partial seizures

Dec. 12, 2008

Olanzapine long-acting injection approved in Europe for schizophrenia

Dec. 12, 2008

Preliminary phase II data suggest APD-125 did not meet trial endpoints

Dec. 12, 2008

AcelRx reports results from phase II clinical study of sufentanil in postoperative pain

Dec. 12, 2008

Phosphagenics presents phase I clinical results for transdermal lidocaine

Dec. 12, 2008

Sosei reports positive results from two phase I trials of SD-118 for neuropathic pain

Dec. 11, 2008

New therapeutic agents for AD and other neurological disorders reported in recent patents

Dec. 11, 2008

Novel analgesic agents reported in recent patent literature

Dec. 11, 2008

AstraZeneca and Targacept present top-line results from phase IIb AZD-3480 trial

Dec. 10, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...